Long-Term Correction of Glycogen Storage Disease Type III by AAV-Mediated Gene Therapy Using a Dual Promoter to Express Bacterial Pullulanase

被引：0
|
作者：
Lim, Jeong-A [1 ]
Choi, Su Jin [1 ]
Kishnani, Priya S. [1 ]
Sun, Baodong [1 ]
机构：
[1] Duke Univ, Durham, NC USA
来源：
MOLECULAR THERAPY | 2022年 / 30卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
246
引用
收藏
页码：119 / 120
页数：2
相关论文
共 50 条
  • [1] AAV-Mediated Gene Therapy for Glycogen Storage Disease Type III Using a Bacterial Glycogen Debranching Enzyme
    Lim, Jeong-A
    Choi, Su Jin
    Gao, Fengqin
    Kishnani, Priya S.
    Sun, Baodong
    MOLECULAR THERAPY, 2020, 28 (04) : 307 - 308
  • [2] Systemic Correction of Murine Glycogen Storage Disease Type IV by an AAV-Mediated Gene Therapy
    Yi, Haiqing
    Zhang, Quan
    Brooks, Elizabeth D.
    Yang, Chunyu
    Thurberg, Beth L.
    Kishnani, Priya S.
    Sun, Baodong
    HUMAN GENE THERAPY, 2017, 28 (03) : 286 - 294
  • [3] Long-term safety and efficacy of AAV gene therapy in the canine model of glycogen storage disease type Ia
    Lee, Young Mok
    Conlon, Thomas J.
    Specht, Andrew
    Coleman, Kirsten E.
    Brown, Laurie M.
    Estrella, Ana M.
    Dambska, Monika
    Dahlberg, Kathryn R.
    Weinstein, David A.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2018, 41 (06) : 977 - 984
  • [4] Correction of Glycogen Storage Disease Type III with an AAV Vector Encoding a Bacterial Glycogen Debranching Enzyme
    Lim, Jeong-A
    Choi, Su Jin
    Gao, Fengqin
    Kishnani, Priya
    Sun, Baodong
    MOLECULAR THERAPY, 2019, 27 (04) : 17 - 17
  • [5] AAV-mediated gene therapy for galactosialidosis: A long-term safety and efficacy study
    Fremuth, Leigh E.
    Hu, Huimin
    van de Vlekkert, Diantha
    Weesner, Jason A.
    Gomero, Elida M.
    d'Azzo, Alessandra
    MOLECULAR GENETICS AND METABOLISM, 2023, 138 (02) : 44 - 44
  • [6] AAV-mediated gene therapy for galactosialidosis: A long-term safety and efficacy study
    Hu, Huimin
    Mosca, Rosario
    Gomero, Elida
    van de Vlekkert, Diantha
    Campos, Yvan
    Fremuth, Leigh E.
    Brown, Scott A.
    Weesner, Jason A.
    Annunziata, Ida
    d'Azzo, Alessandra
    MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2021, 23 : 644 - 658
  • [7] Long-term correction of glycogen storage disease type II with a hybrid Ad-AAV vector
    Sun, BD
    Chen, YT
    Bird, A
    Amalfitano, A
    Koeberl, DD
    MOLECULAR THERAPY, 2003, 7 (02) : 193 - 201
  • [8] Waning efficacy in a long-term AAV-mediated gene therapy study in the murine model of Krabbe disease
    Heller, Gregory J.
    Marshall, Michael S.
    Issa, Yazan
    Marshall, Jeffrey N.
    Nguyen, Duc
    Rue, Emily
    Pathmasiri, Koralege C.
    Domowicz, Miriam S.
    van Breemen, Richard B.
    Tai, Leon M.
    Cologna, Stephanie M.
    Crocker, Stephen J.
    Givogri, Maria, I
    Sands, Mark S.
    Bongarzone, Ernesto R.
    MOLECULAR THERAPY, 2021, 29 (05) : 1883 - 1902
  • [9] AAV vector-based gene therapy for glycogen storage disease type III
    Vidal, P.
    Jauze, L.
    Le Brun, P. R.
    Charles, S.
    Collaud, F.
    Daniele, N.
    Van Wittenberghe, L.
    Gjata, B.
    Laforet, P.
    Malfatti, E.
    Mingozzi, F.
    Ronzitti, G.
    HUMAN GENE THERAPY, 2018, 29 (12) : A140 - A140
  • [10] Disease correction by AAV-mediated gene therapy in a new mouse model of mucopolysaccharidosis type IIID
    Roca, Carles
    Motas, Sandra
    Marco, Sara
    Ribera, Albert
    Sanchez, Victor
    Sanchez, Xavier
    Bertolin, Joan
    Leon, Xavier
    Perez, Jennifer
    Garcia, Miguel
    Villacampa, Pilar
    Ruberte, Jesus
    Pujol, Anna
    Haurigot, Virginia
    Bosch, Fatima
    HUMAN MOLECULAR GENETICS, 2017, 26 (08) : 1535 - 1551
12345